SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-21-000127
Filing Date
2021-05-17
Accepted
2021-05-17 07:02:55
Documents
14
Period of Report
2021-05-17
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20210517.htm   iXBRL 8-K 42507
2 EX-99.1 pressreleaseexhibit99q12021.htm EX-99.1 57479
6 image_01.jpg GRAPHIC 5507
  Complete submission text file 0001725160-21-000127.txt   263647

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20210517.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20210517_lab.xml EX-101.LAB 25998
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20210517_pre.xml EX-101.PRE 13731
7 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20210517_htm.xml XML 11807
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 21927491
SIC: 2834 Pharmaceutical Preparations